These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28264853)

  • 41. Minocycline: an old drug for a new bug: multidrug-resistant Acinetobacter baumannii.
    Goff DA; Kaye KS
    Clin Infect Dis; 2014 Dec; 59 Suppl 6():S365-6. PubMed ID: 25371511
    [No Abstract]   [Full Text] [Related]  

  • 42. Tetracyclines for multidrug-resistant Acinetobacter baumannii infections.
    Falagas ME; Vardakas KZ; Kapaskelis A; Triarides NA; Roussos NS
    Int J Antimicrob Agents; 2015 May; 45(5):455-60. PubMed ID: 25801348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
    Cai X; Yang Z; Dai J; Chen K; Zhang L; Ni W; Wei C; Cui J
    Int J Antimicrob Agents; 2017 May; 49(5):609-616. PubMed ID: 28315729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
    Xie J; Roberts JA; Alobaid AS; Roger C; Wang Y; Yang Q; Sun J; Dong H; Wang X; Xing J; Lipman J; Dong Y
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607024
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia.
    Wood GC; Hanes SD; Boucher BA; Croce MA; Fabian TC
    Intensive Care Med; 2003 Nov; 29(11):2072-6. PubMed ID: 14556048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic options for Acinetobacter baumannii infections.
    Vila J; Pachón J
    Expert Opin Pharmacother; 2008 Mar; 9(4):587-99. PubMed ID: 18312160
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model.
    Kang AD; Smith KP; Berg AH; Truelson KA; Eliopoulos GM; McCoy C; Kirby JE
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
    Koomanachai P; Crandon JL; Banevicius MA; Peng L; Nicolau DP
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5060-3. PubMed ID: 19738006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
    Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
    J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of tigecycline against Acinetobacter baumannii isolates from a teaching hospital in Malaysia.
    Dhabaan GN; AbuBakar S; Shorman MA; Hassan H
    J Chemother; 2012 Apr; 24(2):87-92. PubMed ID: 22546763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection.
    Principe L; Capone A; Mazzarelli A; D'Arezzo S; Bordi E; Di Caro A; Petrosillo N
    Microb Drug Resist; 2013 Oct; 19(5):407-14. PubMed ID: 23659601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis.
    Cunha BA
    J Clin Microbiol; 2009 May; 47(5):1613. PubMed ID: 19403778
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
    Ni W; Cui J; Liang B; Cai Y; Bai N; Cai X; Wang R
    J Antibiot (Tokyo); 2013 Dec; 66(12):705-8. PubMed ID: 23981963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia?
    Tasbakan MS; Pullukcu H; Sipahi OR; Tasbakan MI; Aydemir S; Bacakoglu F
    J Chemother; 2011 Dec; 23(6):345-9. PubMed ID: 22233818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SPR741, an Antibiotic Adjuvant, Potentiates the
    Zurawski DV; Reinhart AA; Alamneh YA; Pucci MJ; Si Y; Abu-Taleb R; Shearer JP; Demons ST; Tyner SD; Lister T
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947471
    [No Abstract]   [Full Text] [Related]  

  • 57. Nosocomial outbreak of a multiresistant Acinetobacter baumannii expressing OXA-23 carbapenemase in Spain.
    Merino M; Poza M; Roca I; Barba MJ; Sousa MD; Vila J; Bou G
    Microb Drug Resist; 2014 Aug; 20(4):259-63. PubMed ID: 24328852
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
    Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii.
    Córdoba J; Coronado-Álvarez NM; Parra D; Parra-Ruiz J
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7316-9. PubMed ID: 26369956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.
    Jaruratanasirikul S; Wongpoowarak W; Wattanavijitkul T; Sukarnjanaset W; Samaeng M; Nawakitrangsan M; Ingviya N
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7236-7244. PubMed ID: 27671056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.